← Back to Search

Repetitive Transcranial Magnetic Stimulation

High-frequency rTMS for Depression

N/A
Waitlist Available
Led By Jonathan Downar, MD PhD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, after each week (10 sessions) of treatment, and 2, 6, and 12 weeks post-treatment
Awards & highlights

Study Summary

This trial will compare the efficacy and tolerability of 20 Hz vs. 1 Hz vs. sham repetitive transcranial magnetic stimulation targeting the dorsomedial prefrontal cortex, delivered twice daily over 15 days, in patients with a diagnosis of major depressive disorder. The trial will include structural and functional MRI, EEG, and behavioral measures obtained before, during, and after treatment.

Eligible Conditions
  • Depression

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, after each week (10 sessions) of treatment, and 2, 6, and 12 weeks post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, after each week (10 sessions) of treatment, and 2, 6, and 12 weeks post-treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
HAM-D17 score
Secondary outcome measures
Beck Depression Inventory-II
Beck anxiety inventory
Other outcome measures
Electroencephalography
Resting-state functional MRI

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Low-frequency rTMSExperimental Treatment1 Intervention
1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
Group II: High-frequency rTMSExperimental Treatment1 Intervention
20 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
Group III: Sham rTMSPlacebo Group1 Intervention
Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
High-frequency rTMS
2016
N/A
~130

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,465 Previous Clinical Trials
483,569 Total Patients Enrolled
52 Trials studying Depression
11,906 Patients Enrolled for Depression
Jonathan Downar, MD PhDPrincipal InvestigatorUniversity Health Network, Toronto
1 Previous Clinical Trials
90 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
High-frequency vs. Low-frequency vs. Sham DMPFC-rTMS for Major Depression
Jonathan Downar 2016. "High-frequency vs. Low-frequency vs. Sham DMPFC-rTMS for Major Depression". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02702154.
All > Major Depressive Disorder
~13 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top